http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011503231-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-062 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011503231-A |
| titleOfInvention | Peptides for treatment of HCV infection |
| abstract | Disclosed is a novel peptide that is a derivative of boceprevir. The present invention relates to novel compounds which are peptide derivatives and pharmaceutically acceptable salts thereof. More specifically, the present invention relates to a novel peptide that is a derivative of boceprevir. The invention also relates to compositions comprising one or more compounds of the invention and a carrier, and methods of treating diseases and conditions that are beneficially treated by administering an HCV NS3 / NS4A protease inhibitor, such as boceprevir. Use of the disclosed compounds and compositions is provided. [Selection figure] None |
| priorityDate | 2007-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 421.